This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01567/identifier/chemspider/
n12http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01567/identifier/chebi/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01567/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01567/identifier/wikipedia/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01567/identifier/pubchem-compound/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/ontology/mesh/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01567/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01567/identifier/kegg-drug/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01567/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01567
rdf:type
n5:Drug
n5:description
Fludiazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is a scheduled drug in the U.S., but is approved for use in Japan.
n5:generalReferences
# Ishiwata K, Yanai K, Ido T, Miura-Kanno Y, Kawashima K: Synthesis and biodistribution of [11C]fludiazepam for imaging benzodiazepine receptors. Int J Rad Appl Instrum B. 1988;15(4):365-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2855634 # Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2857046
n5:group
approved illicit
n5:indication
Used for the short-term treatment of anxiety disorders.
owl:sameAs
n4:DB01567 n18:DB01567
dcterms:title
Fludiazepam
adms:identifier
n8:PA164745609 n13:3369 n14:46507563 n15:DB01567 n16:D01354 n17:31618 n19:3252 n21:Fludiazepam
n5:mechanismOfAction
Fludiazepam has similar action to diazepam, but binds with four times more affinity to benzodiazepine receptors than diazepam.
n5:synonym
Erispan Fludiazepamum 7-chloro-5-(O-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one
n5:toxicity
Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
n5:foodInteraction
Avoid taking with grapefruit juice. Avoid excessive quantities of coffee or tea (Caffeine). Avoid alcohol.
n5:synthesisReference
Yamamato, H., Inaba, S.,Okamoto, T., Hirohashi, T., Ishizumi, K., Yamamoto, M., Maruyama, l., Mori, K. and Kobayashi, T.; U.S. Patents 3,723,461; March 27, 1973; 3,828,027; August 6, 1974 and 3,925,364; December 9, 1975; all assigned to Sumitomo Chemical Co., Ltd.
n11:hasConcept
n12:M0048226
n5:IUPAC-Name
n6:271B5659-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B565F-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B565E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B565B-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B565C-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B565D-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5657-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5655-363D-11E5-9242-09173F13E4C5 n6:271B566F-363D-11E5-9242-09173F13E4C5 n6:271B5658-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5656-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:N05BA17
n5:H-Bond-Acceptor-Count
n6:271B5665-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5666-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5660-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5661-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5663-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5662-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5664-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
3900-31-0
n5:category
n5:Bioavailability
n6:271B566A-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B566C-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B566D-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B566E-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5669-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5668-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B566B-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B565A-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5667-363D-11E5-9242-09173F13E4C5